Published in Virchows Arch on February 01, 2007
AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma. World J Gastroenterol (2007) 1.10
Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha. Am J Pathol (2009) 1.00
Resistance of cholangiocarcinoma cells to parthenolide-induced apoptosis by the excretory-secretory products of Clonorchis sinensis. Parasitol Res (2008) 0.96
Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer. Medscape J Med (2008) 0.81
Increased expression of α-methylacyl-coenzyme A racemase (AMACR; p504s) and p16 in distal hyperplastic polyps. Diagn Pathol (2013) 0.80
Prognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: a meta-analysis. Arch Med Sci (2016) 0.79
Reappraisal of the therapeutic role of celecoxib in cholangiocarcinoma. PLoS One (2013) 0.78
Histological changes caused by meclofenamic acid in androgen-independent prostate cancer tumors: evaluation in a mouse model. Int Braz J Urol (2015) 0.75
The measurement of observer agreement for categorical data. Biometrics (1977) 216.56
Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology (2001) 5.12
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res (1998) 3.79
Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem (2001) 3.69
Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells. J Biol Chem (1990) 3.02
Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res (1991) 2.30
Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology (1999) 2.05
Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol (1994) 1.82
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer (2001) 1.61
The pathology of Clonorchis sinensis infestation of the liver. J Pathol Bacteriol (1955) 1.54
ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology (2002) 1.54
P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J (2002) 1.48
Positive and negative regulation of NF-kappaB by COX-2: roles of different prostaglandins. J Biol Chem (2001) 1.44
Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hum Pathol (1985) 1.34
Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis. Chest (2005) 1.30
Induction of cyclo-oxygenase-2 by cytokines in human cultured airway smooth muscle cells: novel inflammatory role of this cell type. Br J Pharmacol (1997) 1.24
Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res (2004) 1.21
p53 Mutations in human cholangiocarcinoma: a review. Liver Int (2005) 1.11
The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther (2004) 1.11
Point mutation of K-ras gene codon 12 in biliary tract tumors. Gastroenterology (1994) 1.10
Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. Semin Liver Dis (2002) 1.09
Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch (2004) 1.07
Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. Cancer (2001) 1.05
Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology (2004) 1.02
Akt expression may predict favorable prognosis in cholangiocarcinoma. J Gastroenterol Hepatol (2006) 1.02
Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest (1999) 1.01
COX-2 regulates p53 activity and inhibits DNA damage-induced apoptosis. Biochem Biophys Res Commun (2005) 1.01
Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol Cancer Ther (2003) 1.00
Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma. Gut (2001) 0.99
Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hepatology (2001) 0.98
Chemoprevention in hereditary colorectal cancer syndromes. Cancer (1999) 0.92
Expression of cyclooxygenase-2 in cholangiocarcinoma: correlation with clinicopathological features and prognosis. J Gastroenterol Hepatol (2004) 0.81
Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg (2012) 19.78
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol (2009) 5.57
ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies: results of a multicenter analysis. World J Surg (2014) 3.60
Inflammatory reactions and severe neutropenia in mice lacking the transcriptional repressor Gfi1. Nat Genet (2002) 2.87
Right-liver living donor transplantation for decompensated end-stage liver disease. Liver Transpl (2002) 2.86
Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med (2009) 2.80
Euthyroid goiter with and without nodules--diagnosis and treatment. Dtsch Arztebl Int (2012) 2.79
Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. Liver Int (2008) 1.95
The White test: a new dye test for intraoperative detection of bile leakage during major liver resection. Arch Surg (2008) 1.86
Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer (2005) 1.73
Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol (2007) 1.71
Clinical, molecular, and genomic changes in response to a left ventricular assist device. J Am Coll Cardiol (2011) 1.69
High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol (2009) 1.62
Recurrent high-grade leiomyosarcoma with heterologous osteosarcomatous differentiation. Virchows Arch (2005) 1.40
Minimally invasive versus open esophagectomy: meta-analysis of outcomes. Dig Dis Sci (2010) 1.35
Right living donor liver transplantation: an option for adult patients: single institution experience with 74 patients. Ann Surg (2003) 1.31
Achalasia: will genetic studies provide insights? Hum Genet (2010) 1.30
Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation (2002) 1.27
Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol (2004) 1.26
Living donor liver transplantation for hepatocellular carcinoma: a single-center preliminary report. Liver Transpl (2006) 1.20
Comparison between minimally invasive video-assisted thyroidectomy and conventional thyroidectomy: is there any evidence-based information? Thyroid (2008) 1.19
High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome. Breast Cancer Res (2005) 1.19
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res (2009) 1.18
Survivin determines cardiac function by controlling total cardiomyocyte number. Circulation (2008) 1.18
Visceral artery aneurysms: Incidence, management, and outcome analysis in a tertiary care center over one decade. Eur Radiol (2015) 1.16
Multiple endocrine neoplasia type 2. Best Pract Res Clin Endocrinol Metab (2010) 1.11
Hemodynamic support by left ventricular assist devices reduces cardiomyocyte DNA content in the failing human heart. Circulation (2010) 1.09
Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med (2012) 1.08
Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3. Endocr Relat Cancer (2012) 1.05
Toll-like receptor 4 variant D299G induces features of neoplastic progression in Caco-2 intestinal cells and is associated with advanced human colon cancer. Gastroenterology (2011) 1.05
Endoscopic and surgical resection of T1a/T1b esophageal neoplasms: a systematic review. World J Gastroenterol (2013) 1.05
Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed. J Thorac Oncol (2013) 1.04
Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach? Dig Dis Sci (2008) 1.03
The role of surgery in Caroli's disease. J Am Coll Surg (2006) 1.03
Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements. Mod Pathol (2007) 1.03
Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT. J Nucl Med (2014) 1.02
Diagnostic approach to interstitial pneumonias in a single centre: report on 88 cases. Diagn Pathol (2012) 1.02
Experience after the evaluation of 700 potential donors for living donor liver transplantation in a single center. Liver Transpl (2004) 1.02
Topography of the extrinsic internal anal sphincter nerve supply during laparoscopic-assisted TAMIS TME: five key zones of risk from the surgeons' view. Int J Colorectal Dis (2014) 1.02
Inhibition of protein phosphatase 1 by inhibitor-2 exacerbates progression of cardiac failure in a model with pressure overload. Cardiovasc Res (2008) 1.01
Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma. J Thorac Oncol (2012) 1.00
Intraoperative application of "white test" to reduce postoperative bile leak after major liver resection: results of a prospective cohort study in 137 patients. Langenbecks Arch Surg (2008) 1.00
Liver transplantation for hepatocellular carcinoma in cirrhosis within the Eurotransplant area: an additional option with "livers that nobody wants". Transplantation (2005) 0.99
Liver transplantation for hepatocellular carcinoma: University Hospital Essen experience and metaanalysis of prognostic factors. J Am Coll Surg (2007) 0.99
Orthotopic liver transplantation: T-tube or not T-tube? Systematic review and meta-analysis of results. Transplantation (2009) 0.98
Risk of lymph node metastasis in submucosal esophageal cancer: a review of surgically resected patients. Expert Rev Gastroenterol Hepatol (2011) 0.98
Comparison of the sixth and the seventh editions of the UICC classification for perihilar cholangiocarcinoma. Ann Surg Oncol (2012) 0.97
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer (2011) 0.97
The use of self-expanding stents in esophageal and gastroesophageal junction cancer palliation: a meta-analysis and meta-regression analysis of outcomes. Dig Dis Sci (2010) 0.97
Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy. Int J Cancer (2011) 0.97
Diagnosis and treatment of pancreatic metastases of a papillary thyroid carcinoma. Thyroid (2010) 0.97
Multidisciplinary management of gastric and gastroesophageal cancers. World J Gastroenterol (2008) 0.97
Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma. Liver Int (2008) 0.97
Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic? Transplantation (2005) 0.96
Differential expression of microRNA 181b and microRNA 21 in hyperplastic polyps and sessile serrated adenomas of the colon. Virchows Arch (2009) 0.96
GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res (2005) 0.96
CD4+CD25+ T-cell populations expressing CD134 and GITR are associated with disease activity in patients with Wegener's granulomatosis. Nephrol Dial Transplant (2008) 0.96
Detection of lymph node metastases in esophageal cancer. Expert Rev Anticancer Ther (2011) 0.95
Fulminant septic shock due to Clostridium perfringens skin and soft tissue infection eight years after liver transplantation. Ann Transplant (2011) 0.95
Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma. Int J Cancer (2011) 0.95
Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int (2009) 0.95
Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. Eur J Cancer (2013) 0.93
Degraded collagen induces calpain-mediated apoptosis and destruction of the X-chromosome-linked inhibitor of apoptosis (xIAP) in human vascular smooth muscle cells. Cardiovasc Res (2005) 0.93
Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab. Histochem Cell Biol (2011) 0.93
Rare expression of target antigens for immunotherapy on disseminated tumor cells in breast cancer patients without overt metastases. Int J Mol Med (2003) 0.92
T lymphocytes export proteasomes by way of microparticles: a possible mechanism for generation of extracellular proteasomes. J Cell Mol Med (2013) 0.91
Klatskin-mimicking lesions: still a diagnostical and therapeutical dilemma? Hepatogastroenterology (2011) 0.91
FFPE tissue as a feasible source for gene expression analysis--a comparison of three reference genes and one tumor marker. Pathol Res Pract (2013) 0.91
Alveolar extracellular 20S proteasome in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med (2009) 0.91
Surgical treatment of pancreatic metastases of renal cell carcinoma. JOP (2005) 0.90
Cholangiocellular carcinoma--the role of caudate lobe resection and mesohepatectomy. HPB (Oxford) (2008) 0.89
Lung cancer during pregnancy involving the products of conception and a review of the literature. Arch Gynecol Obstet (2002) 0.89
Hypothermic reconditioning of porcine kidney grafts by short-term preimplantation machine perfusion. Transplantation (2012) 0.89
The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer. Gynecol Oncol (2010) 0.88
Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology. Eur J Nucl Med Mol Imaging (2014) 0.88
Biliary reconstruction following right adult living donor liver transplantation end-to-end or end-to-side duct-to-duct anastomosis. Langenbecks Arch Surg (2002) 0.88
Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer. Oncol Rep (2008) 0.88
The action of small GTPases Rab11 and Rab25 in vesicle trafficking during cell migration. Cell Physiol Biochem (2012) 0.88
The zinc finger protein and transcriptional repressor Gfi1 as a regulator of the innate immune response. Immunobiology (2008) 0.88
No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemia. Pharmacogenet Genomics (2006) 0.88
Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways. Int J Cancer (2010) 0.87
High insulin-like growth factor mRNA-binding protein 3 (IMP3) protein expression is associated with poor survival in muscle-invasive bladder cancer. BJU Int (2012) 0.87
The BRAF V600E mutation in papillary thyroid carcinoma is associated with glucose transporter 1 overexpression. Thyroid (2012) 0.87
GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma. Neoplasia (2007) 0.87